Gorbakov V V, Galik V P, Kirillov S M
Ter Arkh. 1998;70(10):82-6.
Heptral trial in alcoholic, drug and viral diseases of the liver.
67 patients with chronic diffuse liver diseases were treated with heptral. The examination covered AlAt, AP, HHTP, bilirubin, cholesterol, CT of the liver, esophagogastroduodenoscopy. Heptral was given by two steps: 14 days of intravenous drops (800 mg/day) followed by 14 days of oral use (2 tablets, 400 mg each) before meal at 8 a.m. and 2 p.m.
In alcoholic disease of the liver, heptral relieved depression, reduced AlAT, AP, HHTP, bilirubin, density of the liver. The addition of heptral to interferon-alpha-2 treatment of chronic hepatitis C corrected intrahepatic cholestasis. In drug-induced liver damage heptral promoted normalization of the hepatic tests, improved general condition of the patients.
Heptral is effective in patients with alcoholic and drug liver lesions, chronic hepatitis C.
进行肝得乐治疗酒精性、药物性和病毒性肝病的试验。
67例慢性弥漫性肝病患者接受肝得乐治疗。检查项目包括谷丙转氨酶、碱性磷酸酶、透明质酸、胆红素、胆固醇、肝脏CT、食管胃十二指肠镜检查。肝得乐分两个阶段给药：静脉滴注14天（800毫克/天），随后口服14天（每次2片，每片400毫克），于上午8点和下午2点饭前服用。
在酒精性肝病中，肝得乐缓解了抑郁症状，降低了谷丙转氨酶、碱性磷酸酶、透明质酸、胆红素及肝脏密度。在慢性丙型肝炎的α-2干扰素治疗中加用肝得乐可纠正肝内胆汁淤积。在药物性肝损伤中，肝得乐促使肝脏检查结果恢复正常，改善了患者的总体状况。
肝得乐对酒精性和药物性肝损伤、慢性丙型肝炎患者有效。
